Effect of high doses of oral risedronate ([amount hidden]) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.

This single-center descriptive, double-blind, placebo-controlled, randomized, parallel group study included 32 postmenopausal white women with at least one radiographically confirmed vertebral compression fracture.

The biological response was investigated by measuring serum calcium, parathyroid hormone (PTH), and 2 h urinary pyridinoline/creatinine (Pyr/Cr) and deoxypyridinoline/creatinine (DPyr/Cr) ratios at baseline and at days 3, 7, 14, 21, 28, 35, 42, 49, 56, and 84.

Who Took Part

The abstract describes 32 women taking part.

PubMed indexes the participants as middle-aged adults and older adults, women only.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the women and researchers unaware of who received Parathyroid Hormone (PTH 1-84).

The comparison arm used a placebo, so changes seen with Parathyroid Hormone (PTH 1-84) could be set against what happens without it.

The Parathyroid Hormone (PTH 1-84) group and the comparison group ran side by side rather than switching.

The methods mention a period of 14 days.

What Was Measured

The biological response was investigated by measuring serum calcium, parathyroid hormone (PTH), and 2 h urinary pyridinoline/creatinine (Pyr/Cr) and deoxypyridinoline/creatinine (DPyr/Cr) ratios at baseline and at days 3, 7, 14, 21, 28, 35, 42, 49, 56, and 84.

In groups R-P, R-CP-P, and R-CP-R-CP, mean serum PTH levels were elevated above baseline values for the entire 56 day treatment period and remained elevated, although to a lesser extent, at the day 84 follow-up visit.

PubMed files the paper under topics including Calcium Channel Blockers, Collagen, Cross-Linking Reagents, Etidronic Acid, Osteoporosis, Postmenopausal, Parathyroid Hormone and Risedronic Acid.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in 32 women over 14 days.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2001 (Bone), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.